01
Clinical
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 - NEC
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 NEC
NEC — applies its AI neoantigen-prediction platform to personalized vaccines (NECVAX-NEO1) and powers partners' pipelines.
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 NEC
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. This super composite rating is th…
A five-organization consortium of NEC, Taiho Pharmaceutical, the Japanese Foundation for Cancer Research, AIST, and Waseda University was selected under NEDO's Large-Scale Demonstration for Use Case Creation (Post-5G ICT infrastructure program) to build a quantum-computing-based computational and evaluation platform for next-generation cancer immunotherapy, integrating quantum computing, AI, drug discovery, and immunology to enable optimal design and immunological validation. The implication: a pharma sponsor plus national institutes treating immunotherapy design as a government-funded compute-infrastructure problem rather than a one-off pipeline asset.
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) among patients treated with the individualized neoantigen therapeutic vaccine TG4050 in the Phase 1 portion of a randomized Phase 1/2 trial in resected, locally advanced HPV-negative…